- Home
- AIO vs EMBC Comparison
AIO vs EMBC Comparison
Compare AIO & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- EMBC
- Stock Information
- Founded
- AIO 2019
- EMBC 1924
- Country
- AIO United States
- EMBC United States
- Employees
- AIO N/A
- EMBC N/A
- Industry
- AIO Finance/Investors Services
- EMBC Medical/Dental Instruments
- Sector
- AIO Finance
- EMBC Health Care
- Exchange
- AIO Nasdaq
- EMBC Nasdaq
- Market Cap
- AIO 808.3M
- EMBC 726.8M
- IPO Year
- AIO N/A
- EMBC N/A
- Fundamental
- Price
- AIO $24.30
- EMBC $10.39
- Analyst Decision
- AIO
- EMBC Hold
- Analyst Count
- AIO 0
- EMBC 3
- Target Price
- AIO N/A
- EMBC $17.00
- AVG Volume (30 Days)
- AIO 141.5K
- EMBC 688.2K
- Earning Date
- AIO 01-01-0001
- EMBC 08-08-2025
- Dividend Yield
- AIO 9.05%
- EMBC 5.72%
- EPS Growth
- AIO N/A
- EMBC N/A
- EPS
- AIO N/A
- EMBC 0.89
- Revenue
- AIO N/A
- EMBC $1,079,500,000.00
- Revenue This Year
- AIO N/A
- EMBC N/A
- Revenue Next Year
- AIO N/A
- EMBC N/A
- P/E Ratio
- AIO N/A
- EMBC $11.75
- Revenue Growth
- AIO N/A
- EMBC N/A
- 52 Week Low
- AIO $15.09
- EMBC $9.20
- 52 Week High
- AIO $20.25
- EMBC $21.48
- Technical
- Relative Strength Index (RSI)
- AIO 55.54
- EMBC 50.88
- Support Level
- AIO $24.38
- EMBC $9.97
- Resistance Level
- AIO $24.78
- EMBC $10.87
- Average True Range (ATR)
- AIO 0.33
- EMBC 0.45
- MACD
- AIO -0.08
- EMBC 0.14
- Stochastic Oscillator
- AIO 61.40
- EMBC 71.47
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About EMBC Embecta Corp.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.